[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-disorders":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,53,85,122,149,180,210,242,270,294,316,342],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053488","diaphragmatic-breathing-exercises-on-sleep-disorders-un-polycystic-ovarian-syndrome-100053488",false,"NCT07698925","Diaphragmatic Breathing Exercises on Sleep Disorders un Polycystic Ovarian Syndrome","Effect of Diaphragmatic Breathing on Sleep Disorders in Polycystic Ovarian Syndrome","Inclusion Criteria:\n\n* Women aged from 25-35 years old, Diagnosed with PCOS by gynecologist, diagnosis of PCOS will be based on the 2003 Rotterdam criteria.\n\n  * They have a Pittsburgh sleep quality index (PSQI) score greater than 5.\n  * Not participating in any physical exercise for the previous 3 months.\n  * They have an insomnia severity index score greater than 15.\n  * They have a fatigue severity scale score greater than 36.\n  * Ability to use internet and phone services\n\nExclusion Criteria:\n\n* • Women with autoimmune diseases and cancer.\n\n  * Women with neurological, mental, cardiopulmonary and musculoskeletal disorders.\n  * Pregnant or lactating women.\n  * Women who showed regular adherence to sleeping pills, antidepressants and hormonal replacement agents.\n  * Inability to perform diaphragmatic breathing due to physical limitations.\n  * Women who participate or receive any interventions that could affect their sleep","FEMALE","25 Years","35 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"NA","Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in females in reproductive age and not completely understood. Women with PCOS appear to have an increased frequency of sleep problems. Diaphragmatic Breathing (DB) exercises has positive effects on improving sleep quality. The purpose of this study will evaluate the effect of diaphragmatic breathing exercises on improving sleep quality in polycystic ovarian syndrome women.",[27,28,29,30,31,32],"Polycystic Ovarian Syndrome (PCOS)","Pittsburg Sleep Quality Index","Fatigue Severity Scale","Insomnia Severity Index","Diaphragmatic Breathing Exercise","Sleep Disorders",[34,35,36,37,38,39],"Polycystic ovary syndrome","Diaphragmatic breathing exercises","Sleep disorders","Pittsburg sleep quality index","Insomnia severity index","Fatigue severity scale","RECRUITING","2026-07-10",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":44},"2025-08-01",{"date":48,"type":21},"2026-08-30",{"name":50,"class":51},"Adly A Adam","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100356009","validation-of-a-method-of-screening-for-sleep-disorders-in-children-with-cerebral-palsy-using-connected-tools-100356009","NCT03915418","Validation of a Method of Screening for Sleep Disorders in Children With Cerebral Palsy, Using Connected Tools","Validation of a Simple Method of Screening for Sleep Disorders in Children With Cerebral Palsy, Using Connected Tools","SOUTIEN-PC","Inclusion Criteria:\n\n* Boy or girl between 6 and 15 years old\n* Confirmed diagnosis of cerebral palsy\n* GMFCS class\\> 3\n* Parents and child agreement\n\nExclusion Criteria:\n\n* Pharmacological treatment of sleep disorders\n* Diurnal and \u002F or nocturnal ventilatory support\n* Difficulty understanding and \u002F or participation\n* Subjects under 6 and over 15\n* Refusal to participate\n* Not affiliated with and not a beneficiary of a health insurance plan","ALL","6 Years","15 Years",{"count":65,"type":21},140,[24],"Cerebral palsy (CP) is the most common cause of child disability. Nearly 40% of PC children suffer from sleep disorders, which are not routinely screened. The neuro-cognitive, physical and environmental morbidity of sleep disorders should require their diagnosis and management. Limited access to the reference exam (polysomnography or PSG) delays the diagnosis and only allows screening of these disorders for a limited number of PC children. The hypothesis of our study is that connected technologies could optimize screening for sleep disorders in PC children by selecting children requiring PSG exploration and specific management.",[32],[70,71,72,73,74],"Screening","sleep disorders","children","cerebral palsy","connected tools","2026-06-24",{"date":77,"type":44},"2026-06-25",{"date":79,"type":44},"2021-01-12",{"date":81,"type":21},"2027-02",{"name":83,"class":51},"University Hospital, Brest",6,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":61,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":52},"100643630","effect-of-progressive-muscle-relaxation-and-diaphragmatic-breathing-on-sleep-disturbances-in-chemotherapy-patients-100643630","NCT07639710","Effect of Progressive Muscle Relaxation and Diaphragmatic Breathing on Sleep Disturbances in Chemotherapy Patients","Effect of Progressive Muscle Relaxation and Diaphragmatic Breathing Techniques on Sleep Disturbances in Cancer Patients Undergoing Chemotherapy","PMR & DB","Inclusion Criteria:\n\n* • Aged between 40-60 years\n\n  * Both male and female patients\n  * Currently receiving at least the second cycle of chemotherapy\n  * Receiving chemotherapy protocols (Zhou et al., 2022)\n  * PSQI score \\> 5 at baseline indicating poor sleep quality\n  * BMI between 18.5 and 30\n  * Able to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed with sleep disorders unrelated to chemotherapy (e.g., obstructive sleep apnea)\n\n  * Current use of sleep medications or anti-anxiety drugs\n  * Diagnosed with major psychiatric conditions\n  * Cognitive impairment limiting understanding of instructions\n  * Severe cardiopulmonary comorbidities\n  * Recent participation in relaxation-based clinical trials","40 Years","60 Years",{"count":96,"type":21},40,[24],"This randomized controlled trial aims to investigate the effect of combined Progressive Muscle Relaxation (PMR) and Diaphragmatic Breathing (DB) techniques on sleep disturbances among patients receiving chemotherapy. Sleep disturbances are common among cancer patients undergoing chemotherapy and may negatively affect physical recovery, emotional well-being, and quality of life. Participants will be randomly assigned to either an intervention group receiving PMR and DB training in addition to routine care or a control group receiving routine care alone. Sleep outcomes will be assessed using the Pittsburgh Sleep Quality Index (PSQI), sleep diary records, and wearable sleep monitoring devices. The study seeks to determine whether the combined intervention can improve sleep quality and reduce sleep-related problems in chemotherapy patients.",[100,32,101],"Sleep Disturbance","Cancer",[103,100,104,105,106,107,108,109,110,111],"Chemotherapy","Sleep Quality","Progressive Muscle Relaxation","Diaphragmatic Breathing","Relaxation Therapy","Cancer Patients","Sleep Diary","PSQI","Wristband Monitor","NOT_YET_RECRUITING","2026-06-06",{"date":115,"type":44},"2026-06-10",{"date":117,"type":21},"2026-07-01",{"date":119,"type":21},"2026-09-01",{"name":121,"class":51},"Cairo University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":61,"minAge":94,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":52},"100638812","phase-4-intranasal-dexmedetomidine-esketamine-on-sleep-and-cognition-in-older-adults-with-mild-to-moderate-cognitive-impairment-100638812","NCT07610343","Intranasal Dexmedetomidine-esketamine on Sleep and Cognition in Older Adults With Mild-to-moderate Cognitive Impairment","Impact of Intranasal Dexmedetomidine-esketamine on Sleep Quality and Cognitive Function in Older Adults With Mild-to-moderate Cognitive Impairment: a Randomized, Double-blind, and Placebo-controlled Trial","Inclusion Criteria:\n\n1. Aged ≥ 60 years.\n2. Meeting the clinical diagnostic criteria for Alzheimer's disease, with mild cognitive impairment (MoCA score 18-25) or moderate cognitive impairment (MoCA score 10-17) due to Alzheimer's disease.\n3. Comorbid with sleep disorders (Pittsburgh Sleep Quality Index \\[PSQI\\] score ≥ 7).\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Cognitive impairment\u002Fdementia due to other causes (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease dementia).\n2. Unsuitable for intranasal administration due to nasal cavity diseases (e.g., rhinitis, nasal polyps, or nasal congestion of any cause).\n3. Inability to communicate due to visual, auditory, language, or other reasons, or Mini-Mental State Examination (MMSE) score ≤ 9 or MoCA score ≤ 9.\n4. History of schizophrenia, epilepsy, or Parkinson's disease, or confirmed diagnosis of glaucoma, hyperthyroidism, pheochromocytoma, or myasthenia gravis.\n5. Confirmed diagnosis of restless legs syndrome or sleep apnea, or judged to be at high risk of moderate-to-severe sleep apnea according to STOP-Bang score, or Body Mass Index (BMI) \\> 30 kg\u002Fm2.\n6. History of stroke or transient ischemic attack within 12 months prior to enrollment, confirmed intracranial aneurysm, or elevated intracranial pressure from any cause.\n7. Uncontrolled hypertension (e.g., hypertensive crisis or systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg prior to enrollment), myocardial infarction, unstable angina, revascularization surgery within 12 months prior to enrollment, or NYHA class III.\n8. Sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), atrioventricular block above degree II without a pacemaker, corrected QT interval (Fridericia-corrected QTcF) ≥ 450 ms, or other severe arrhythmias (e.g., frequent premature ventricular contractions).\n9. Uncontrolled diabetes (e.g., HbA1c \\> 9%, diabetic ketosis, hyperglycemic coma, or hypoglycemia).\n10. Severe hepatic dysfunction (Child-Pugh Class C), renal dysfunction (eGFR ≤ 30 ml\u002Fmin\u002F1.73m2), respiratory insufficiency (SpO2 \\\u003C 93% on room air), or other severe diseases (e.g., frailty with inability to walk independently, advanced-stage tumors).\n11. Alcohol or drug dependence (manifested as strong cravings, uncontrolled use, and withdrawal symptoms upon cessation), or use of contraindicated medications.\n12. Major surgery under general anesthesia within 12 weeks prior to enrollment, or planned surgery within 12 weeks.\n13. Allergy to dexmedetomidine and\u002For esketamine.\n14. Participation in other interventional clinical studies.\n15. Any other conditions deemed unsuitable for study inclusion by the investigator.",{"count":130,"type":21},60,[132],"PHASE4","Patients with cognitive decline are frequently comorbid with sleep disorders which may in turn aggravate cognitive decline. Sedative dose dexmedetomidine improved sleep quality but incresed bradycardia and hypotension; low dose dexmedetomidine produce less side effects, but the sleep promoting effects are relatively weak. Low dose esketamine also has sleep-promoting effects but may produce neuropsychiatric side effects. Both dexmedetomidine and esketamine are approved for intranasal administration. We suppose that intranasal administration of dexmedetomidine-esketamine combination may improve sleep quality and therefore cognitive function in older ptients with Alzheimer's disease cognitive impairment and sleep disorders.",[135,136,32,137,138],"Older Adults","Cognitive Impairment","Dexmedetomidine","Esketamine",[135,136,32,137,138],"2026-05-28",{"date":142,"type":44},"2026-06-01",{"date":144,"type":21},"2026-06",{"date":146,"type":21},"2027-12",{"name":148,"class":51},"Peking University First Hospital",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":61,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100635039","prediction-of-different-variants-of-sleep-stages-for-the-diagnosis-support-of-chronic-insomnia-and-epilepsy-100635039","NCT07547501","PREDiction of Different Variants of Sleep Stages for the Diagnosis Support of Chronic Insomnia and Epilepsy","PREDSomADICE","Inclusion Criteria\n\n* Patients with chronic insomnia and\u002For epilepsy who underwent polysomnography in a neurophysiology or neurology setting under the responsibility of Pr Navarro between 01 September 2011 and 31 December 2024.\n* Age ≥18 and ≤65 years at the time of the polysomnography recording.\n\nExclusion Criteria\n\n* Severe psychiatric disorder, including decompensated psychotic disorder, manic episode, or major depressive episode with melancholic features.\n* Use of continuous positive airway pressure (CPAP) therapy during the night of recording.\n* Patient refusal or documented opposition to data use.","18 Years","65 Years",{"count":159,"type":21},1500,"OBSERVATIONAL","The objective of this study is to develop and validate deep learning algorithms for automated sleep stage and sub-stage classification using overnight polysomnography data. The models will be trained and evaluated on at least three independent datasets to ensure generalizability.\n\n\\- Primary Outcome Measure : Accuracy of deep learning-based sleep stage classification compared to expert manual scoring (\\>80% target agreement), evaluated across multiple polysomnography datasets including AP-HP (Assistance Publique - Hôpitaux de Paris) data.\n\nThis is a retrospective, observational study.",[163,164,32],"Chronic Insomnia","Epilepsy",[166,167,168,169,170,36,171,164],"Sleep staging","Polysomnography","EEG","Deep learning","Artificial intelligence","Chronic insomnia","2026-04-23",{"date":174,"type":44},"2026-04-29",{"date":144,"type":21},{"date":177,"type":21},"2027-03",{"name":179,"class":51},"Assistance Publique - Hôpitaux de Paris",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":188,"sex":61,"minAge":156,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":52},"100632501","optimization-of-melatonin-administration-in-healthy-adults-100632501","NCT07514507","Optimization of Melatonin Administration in Healthy Adults","Optimizing Timing and Dose of Melatonin Administration: a Randomized, Double-blind Controlled Trial in Healthy Adults","MelOpt","Inclusion Criteria:\n\n* Age between 18 and 45 years of age\n* Fluent knowledge of Italian language\n* Review and signing of the informed consent form\n\nExclusion Criteria:\n\n* Diagnosis of sleep or circadian rhythm disorder\n* Diagnosis of neurological, psychiatric or medical condition that may interfere with sleep\n* Ongoing treatment with medications that may affect sleep, including hypnotics and other types of melatonin\n* Travel to a country with a time zone difference of at least two hours within the two months prior to or during the study\n* Shift work\n* Confirmed pregnancy\n* Breastfeeding",true,"45 Years",{"count":191,"type":21},14,[24],"The goal of this clinical trial is to evaluate whether the timing and dosage of exogenous melatonin can improve sleep onset and maintenance in healthy adults aged 18-45 years (50% female) with no history of sleep disorders.\n\nThe main questions it aims to answer is whether an optimized melatonin administration schedule (4 mg, 3 hours before bedtime) will be more effective in improving sleep initiation and maintenance than an administration schedule more commonly advised (2 mg, 30 minutes before bedtime).\n\nResearchers will compare five conditions involving different combinations of melatonin or placebo administered 30 minutes or 3 hours before bedtime to see if earlier timing and\u002For higher dosage produces better sleep outcomes.\n\nParticipants will:\n\n* Complete a habituation night without any intervention.\n* Undergo five randomized, double-blind experimental sleep conditions including:\n\n  2 mg melatonin 30 minutes before bedtime 2 mg melatonin 3 hours before bedtime 4 mg melatonin 30 minutes before bedtime 4 mg melatonin 3 hours before bedtime Placebo at both time points\n* Be monitored via polysomnography to measure sleep parameters",[32],[196,197,198,199,200],"melatonin","sleep health","sleep drugs","hypnotics and sedatives","drug administration schedule","2026-03-31",{"date":203,"type":44},"2026-04-07",{"date":205,"type":21},"2026-05",{"date":207,"type":21},"2026-08",{"name":209,"class":51},"IRCCS Fondazione Stella Maris",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":188,"sex":61,"minAge":156,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":220,"conditions":221,"keywords":227,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100625773","cognitive-performance-sleep-disturbances-and-fatigue-in-multiple-sclerosis-100625773","NCT07426991","Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis","The Effects of Sleep Disturbances on Fatigue and Cognition in Multiple Sclerosis","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 79 years (all groups)\n* Adequate (corrected) hearing and vision to complete neuropsychological testing (all groups)\n* Sufficient proficiency in German to participate in assessments (all groups)\n* Capacity to provide informed consent and understanding of study procedures (all groups)\n* Diagnosis of MS according to the 2017 revised McDonald criteria (MS group)\n* Indication for sleep medicine evaluation due to at least mild fatigue, operationalized as ≥ 43 points on the Fatigue Scale for Motor and Cognitive Functions (FSMC) (MS group)\n* Indication for sleep medicine evaluation (control group)\n\nExclusion Criteria:\n\n* Lack of signed informed consent or inability to provide consent (all groups)\n* Age \\\u003C 18 years or \\> 79 years (all groups)\n* Presence of another neurological disorder in addition to MS, with the exception of migraine (all groups)\n* Use of medications that influence polysomnographic parameters (e.g., benzodiazepines) (all groups)\n* Uncorrected hearing or vision impairment and\u002For insufficient German language proficiency likely to impact neuropsychological test results (all groups)","79 Years",{"count":219,"type":21},837,"Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity. Sleep disturbances are regarded as a critical factor in the development of fatigue and are frequently observed in individuals with MS. However, they often remain underrecognized, undiagnosed, and consequently untreated.\n\nPolysomnography, the gold standard for assessing sleep architecture and quality, has rarely been applied in the investigation of sleep disorders in MS. Accordingly, uncertainties remain regarding the prevalence and extent to which sleep disturbances contribute to fatigue in this population. Moreover, emerging evidence suggests an association between sleep disorders and cognitive dysfunction in MS. Yet, it is unclear whether cognitive impairment arises from the sleep disorder itself, from the resulting fatigue, or from other independent factors.\n\nPharmacological treatments for MS-related fatigue remain limited, given heterogeneous and frequently non-replicable effects. Non-pharmacological interventions such as physical activity, cognitive behavioral therapy, and psychoeducation have shown promise but yield variable outcomes. The development of novel and effective therapeutic strategies requires a more comprehensive understanding of the etiology of fatigue. To date, the role of sleep disturbances and their relationship to cognitive performance in MS have not been adequately investigated.\n\nThe objective of this project is to determine the prevalence and characteristics of sleep disorders in MS patients with fatigue using polysomnography and to examine their relationship with cognitive impairment. In addition, the study will compare sleep quality parameters and the prevalence of sleep disorders across different MS subtypes (relapsing-remitting, primary progressive, and secondary progressive). Furthermore, within a sub-study, it will be investigated whether the type of immunotherapy has an influence on the aforementioned aspects.\n\nFinally, the project seeks to integrate artificial intelligence (AI) into polysomnography analysis to streamline data evaluation and facilitate the future assessment of therapeutic interventions.\n\nThe study will be conducted as a non-invasive, non-interventional, longitudinal observational trial including MS patients with fatigue and a control group of patients with subjective sleep complaints but without MS. Recruitment will take place over 36 months at two centers: the Department of Neurology at the University Hospital Düsseldorf and the Maria Hilf Clinics in Mönchengladbach. Additional recruitment will be supported by community-based neurologists in the Mönchengladbach region to broaden the study cohort and ensure representativeness of the study population.\n\nApproximately 382 MS patients are expected to be enrolled. The number of control participants will be determined by the proportion of MS patients presenting with sleep disorders and will be recruited consecutively from the neurological sleep laboratory of the Maria Hilf Clinics. For AI training, retrospective polysomnography data from the past five years (N ≥ 10,000 patients) at the Maria Hilf Clinics will be utilized.\n\nThe study protocol includes overnight polysomnography to assess sleep quality, along with comprehensive clinical evaluation, neuropsychological testing, and validated questionnaires addressing fatigue, subjective sleep quality, daytime sleepiness, depression, and anxiety.\n\nBased on manually scored polysomnography, AI models will be trained to identify key parameters of sleep quality. The findings of this study will advance the understanding of the role of sleep disturbances in MS-related fatigue and will facilitate the integration of AI into sleep research, thereby streamlining the evaluation of future therapeutic approaches.",[222,223,224,225,226,32],"Multiple Sclerosis","Remitting-Relapsing Multiple Sclerosis","Primary Progressive Multiple Sclerosis","Secondary Progress Multiple Sclerosis","Fatigue Syndrome, Chronic",[228,229,230,231],"MS","Sleep","Fatigue","Cognition","2026-03-05",{"date":234,"type":44},"2026-03-06",{"date":236,"type":44},"2024-11-01",{"date":238,"type":21},"2028-12",{"name":240,"class":51},"Heinrich-Heine University, Duesseldorf",2,{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":188,"sex":61,"minAge":156,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":52},"100622840","a-longitudinal-follow-up-study-on-predicting-major-depressive-disorder-from-rest-activity-rhythm-profiles-100622840","NCT07388849","A Longitudinal Follow-Up Study on Predicting Major Depressive Disorder From Rest-Activity Rhythm Profiles","Can Rest-Activity Rhythm Profiles Predict Major Depressive Disorder? A Longitudinal Follow-up Study","Inclusion Criteria:\n\n* Hong Kong residents aged 18 to 70 years\n* Chinese language fluency\n* Accessibility to an Internet-enabled mobile device\n* A willingness to provide informed consent and comply with the study protocol\n\nExclusion Criteria:\n\n* Severe medical or neurocognitive disorders that make participation unsuitable\n* History of electroconvulsive therapy (ECT)\n* An unstable use of psychotropic drugs (medication use has to remain stable for at least 6 weeks before baseline assessment)\n* Current involvement in any psychological treatment program that targets depression and\u002For sleep problems\n* The investigators will not exclude those with current suicidal risks (i.e., non-fleeting intent or plan), which is a common symptom of MDD. However, if serious suicidal risk (i.e., PHQ-9 Item 9 score \\> 2) is identified, the participant will be referred to the PI (a clinical psychologist) for further assessment and professional mental health services if deemed necessary.\n\nExclusion criteria for actigraphy assessment:\n\n* Shift work, pregnancy, work, family, or other commitments that interfere with regular sleep-wake patterns\n* Presence of other untreated sleep disorders, including narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)\u002Fperiodic leg movement disorder (PLMD) based on the cut-off scores of individual sections in SLEEP-50 (narcolepsy ≥ 7; OSA ≥ 15; RLS\u002FPLMD ≥ 7)","70 Years",{"count":251,"type":21},160,"This proposed study will be a longitudinal follow-up study of a case-control study of 160 participants (CREC Ref: 2023.234). This study aims to follow up on the trajectory of depression and rest-activity rhythm (RAR) disruptions, as well as examine their association over time. The investigators aim to identify distinctive RAR profiles of MDD using the data from the original project and hypothesize that two or more groups will be identified based on individual RAR variables using cluster analysis. The investigators hypothesize that significant differences in depressive symptom severity, sleep quality, and other outcome measures collected in this follow-up will be found between the clustered groups. Individuals exhibiting the most disrupted RAR profiles are hypothesized to have the greatest deterioration in depression symptom severity and other outcome measures. The investigators also hypothesize that people persisting with MDD will exhibit greater disruptions in RAR compared to those without MDD at the follow-up. Furthermore, the investigators will examine whether individual RAR parameters are longitudinally associated with changes in depression symptom severity and other outcome measures.",[254,32,255],"Major Depressive Disorder (MDD)","Circadian Rhythm",[257,258,259,260],"Actigraphy","Major Depressive Disorder","Rest-activity Rhythm","Longitudinal Study","2026-01-28",{"date":263,"type":44},"2026-02-05",{"date":265,"type":21},"2026-02-01",{"date":267,"type":21},"2029-02-28",{"name":269,"class":51},"Chinese University of Hong Kong",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":61,"minAge":156,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":52},"100615974","sleep-disorders-and-their-impact-on-patients-with-mnires-disease-100615974","NCT07299578","Sleep Disorders and Their Impact on Patients With Ménière's Disease","A Study of Sleep Disorders and Their Impact on Patients With Ménière's Disease","SoM","Inclusion Criteria:\n\n* Adult (≥18 years)\n* Patient followed for Ménière's disease in the ENT department at Strasbourg University Hospital between June 1, 2019, and January 31, 2021.\n\nExclusion Criteria:\n\n* History of intracranial surgery or degenerative neurological disease.\n* No prior sleep medicine consultations.",{"count":279,"type":21},100,"Ménière's disease was first described by Prosper Ménière in 1861 as a balance disorder originating in the inner ear. It is diagnosed based on a characteristic clinical triad of low-frequency hearing loss, tinnitus, and vertigo attacks. The underlying cause is thought to be a pressure imbalance in the inner ear between the endolymphatic and perilymphatic sectors.\n\nThe prevalence of Ménière's disease ranges from 34 to 190 per 100,000 inhabitants.\n\nThe physiology of Ménière's disease is not yet fully understood. It appears that sleep disorders may be related.\n\nIn its 2016 report on Ménière's disease, the French Society of Otolaryngology (SÖL) recommends sleep studies for patients with Ménière's disease.\n\nHowever, these recommendations are based on few studies, which is why we wanted to conduct this research.\n\nThe main hypothesis is the existence of a link between debilitating vertigo and sleep disturbances in patients with Ménière's disease.\n\nIn cases of more significant sleep disturbances in patients with debilitating Ménière's disease, it is important to focus more thoroughly on these disturbances during ENT consultations, which are an integral part of effective multidisciplinary care.",[32],[283,284],"Sleep Disorder","Ménière's Disease","2025-12-09",{"date":287,"type":44},"2025-12-23",{"date":289,"type":44},"2024-07-19",{"date":291,"type":21},"2026-01",{"name":293,"class":51},"University Hospital, Strasbourg, France",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":188,"sex":61,"minAge":156,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":52},"100348068","photomotor-reflex-to-evaluate-the-role-of-the-non-visual-effects-of-light-in-neurological-psychiatric-and-ophthalmological-pathologies-100348068","NCT03811964","Photomotor Reflex to Evaluate the Role of the Non-visual Effects of Light in Neurological, Psychiatric and Ophthalmological Pathologies","Study of the Photomotor Reflex to Evaluate the Role of the Non-visual Effects of Light in Neurological, Psychiatric and Ophthalmological Pathologies","Inclusion Criteria:\n\n* Man or woman\n* Aged 18 years or older\n* Subject having signed a free and informed consent\n* Subject affiliated to a social protection scheme Arm 1 :Subjects with primary sleep-wake disorder Arm 2 : subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep Arm 3 : subject presenting a psychiatric pathology pathology with disorder of the controls of the wake and the sleep Arm 4 : subject presenting an ophthalmological pathology with possible alteration of the photoreception and \u002F or phototransduction Arm 5 : subjects with photosensitivity with regulation disorder of sleep and wake Arm 6 : healthy subject\n\nExclusion Criteria:\n\nAge-Related Macular Degeneration (AMD) and all maculopathies (retinopathies pigmentosa, macular involvement of diabetes)\n\n* Cataract with significant vision loss \\\u003C5\u002F10\n* Chorioretinal neovascularization\n* Subject in exclusion period determined by previous or current study\n* Impossibility to give the subject information enlightened (subject in emergency situation, difficulties of understanding the subject, ...)\n* Subject under the protection of justice\n* Subject under guardianship or curatorship\n* Pregnancy \u002F Breastfeeding",{"count":302,"type":21},726,[24],"The light has visual and non-visual effects on organism and can act on the behavior, the mood, the cognition and the sleep. These effects are mediated by \"classical\" retina photoreceptors which allow vision (rods, cones) but also melanopsin cells. The non-visual effects of light seems to be altered in many neurological, psychiatric or ophtalmological conditions but their exact role in the pathogenesis remains poorly understand. The purpose of the study is to increase our knowledge of the non-visual effects of light and establish new therapeutic applications",[32,306,307,308],"Neurological Pathologies","Psychiatric Pathologies","Ophthalmological Pathologies","2025-08-04",{"date":311,"type":44},"2025-08-08",{"date":313,"type":44},"2020-01-22",{"date":81,"type":21},{"name":293,"class":51},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":188,"sex":61,"minAge":157,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":4},"100588684","impact-of-sleep-disorders-and-digital-support-on-older-peoples-health-100588684","NCT06944600","Impact of Sleep Disorders and Digital Support on Older People's Health","The Role of Sleep Disorders in the Motoric and Cognitive Trajectories of Older Physically Frail Sarcopenic and Healthy Active Subjects","SOMNUS-DARE","Inclusion Criteria:\n\n* Age ≥ 65 years;\n* MMSE score adjusted by age and education ≥ 25\u002F30;\n* Absence of mobility-disability;\n* Absence of need for assistance with Basic Activities of Daily Living (according to the ICFSR International Clinical Practice Guidelines).\n\nExclusion Criteria:\n\n* Individuals with specific clinical conditions that make the intervention unsafe (I.e., severe diseases, unstable health status);\n* Individuals whose adherence to the protocol might be low due to clinical (E.g., cognitive impairment, dialysis) and non-clinical (E.g., plans to relocate out of the study area within the next 3 years) reasons;\n* Individuals unable or unwilling to provide informed consent;\n* Consumption of more than 14 alcoholic drinks per week \\[one alcoholic drink (equal to 14.0 grams of pure alcohol) corresponds to 36 cc of beer (5% alcohol content), 24 cc of malt liquor (7% alcohol content), 15 cc of wine (12% alcohol content), 4.5 cc of distilled spirit or liquor (40% alcohol content)\\];\n* Difficulty in communicating with the study staff due to speech, language, or (non-corrected) hearing and vision problems;\n* Severe arthritis (E.g., awaiting joint replacement) that would interfere with the ability to fully participate in the study;\n* Lung disease requiring regular use of supplemental oxygen;\n* Severe cardiovascular disease (including New York Heart Association \\[NYHA\\] class III or IV, clinically significant congestive heart failure and valvular disease, history of cardiac arrest, presence of an implantable defibrillator or pacemaker, uncontrolled angina);\n* Upper and\u002For lower extremity amputation;\n* Peripheral arterial disease Lériche-Fontaine 3 or 4;\n* Renal disease requiring dialysis;\n* Current enrolment in another study involving lifestyle, nutrition, or pharmaceutical interventions;\n* Further medical, psychiatric, or behavioural factors that in the judgment of the principal investigator may interfere with the study participation;\n* Further possible illnesses affecting the life expectancy and reducing it to less than 24 months, corresponding to the study's length;\n* Clinical judgment concerning safety or non-compliance, as well as the conditions for which the use of the Sleep Profiler is not recommended (sensitivity of skin or scalp and\u002For open wounds on the forehead or scalp, allergic reactions to extended exposure to synthetic fabrics (e.g., polyester, rayon), upper respiratory infection or congestion, head circumference less than 21 or greater than 25 inches, forehead vertical measurement (from top of eyebrows to hairline) less than or equal to 2 inches or horizontal measurement (from hairline to hairline) less than or equal to 6 inches).\n* SPPB score \\\u003C3 at baseline.",{"count":325,"type":21},300,"The goal of this observational study is to learn about the effects of sleep disorders on health and ageing in older people over the age of 65.\n\nThe main question it aims to answer is: How do sleep disorders impact the motoric and cognitive ageing trajectories of older individuals? Participants will undergo a set of instrumental, laboratory and clinical diagnostic examinations to comprehensively assess the impact of sleep disorders on health.",[32,328,136,329,330,331,332],"Frailty","Quality of Life","Ageing","Digital Health","Multidisciplinary Approach","2025-04-17",{"date":335,"type":44},"2025-04-25",{"date":337,"type":21},"2025-05",{"date":339,"type":21},"2027-11",{"name":341,"class":51},"University of Parma",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":61,"minAge":156,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":351,"conditions":352,"keywords":363,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":52},"100566342","study-of-sleep-quality-in-the-intensive-care-unit-and-association-with-weaning-from-invasive-ventilation-in-patients-with-chronic-obstructive-bronchopneumopathy-100566342","NCT06653933","Study of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy.","SLEECOP","Inclusion Criteria:\n\n* Patients diagnosed with COPD according to the GOLD criteria.\n* Mechanical ventilation by endotracheal tube and mechanical ventilation for \\> 24 hours.\n* Withdrawal of treatment with continuous sedation and\u002For neuroleptics.\n* Adequate recovery with Glasgow Coma Scale ≥ 8.\n\nExclusion Criteria:\n\n* Patients with central nervous system damage or neuromuscular pathology.\n* Pregnant or postpartum patients.\n* Patients or their relatives who object to participating in the study.",{"count":350,"type":21},42,"Patients admitted in ICU may require invasive mechanical ventilation, using a mechanical ventilator and an endotracheal tube.\n\nIn ICU, a prolonged duration of invasive mechanical ventilation may be responsible for ventilator-induced lung injury, pulmonary infection, prolonged administration of sedation, neuromyopathy and prolonged length of stay. The goal of the ICU healthcare teams is therefore to reduce the duration of invasive mechanical ventilation as much as possible.\n\nICU patients have many sleep disturbances: sleep fragmentation, sleep stage changes, changes in sleep architecture. These sleep disturbances are due to sedation and analgesia, delirium, patient care activities, noise and altered day-night cycles.\n\nChronic obstructive pulmonary disease (COPD) is a common respiratory disease. COPD complicates the management of invasive mechanical ventilation, particularly weaning of this invasive mechanical ventilation and extubation (removal of the intubation tube).\n\nTo reduce the risk of reintubation, it is recommended that a weaning test is performed prior to extubation. The purpose of this test is to simulate the conditions of breathing without the help of a ventilator after extubation. If the weaning test is successful, the patient can theoretically be extubated.\n\nThere are several causes associated with extubation failure, but studies suggest that sleep deprivation or poor sleep quality in the nights before extubation is one of them. In addition, patients with COPD often have chronic sleep disturbances or induced by their stay in the ICU (asthenia, bed rest, anxiety, sedation, etc.).\n\nThe aim of our study will be to compare the sleep characteristics of COPD patients with a failed weaning test and those with a successful test. Our hypothesis is that patients with a failed weaning test will have more sleep disturbances in the period of 72 hours before the weaning test.",[353,354,355,356,357,358,104,359,32,360,361,362],"COPD","COPD Exacerbation","Ventilated Patients","Ventilator-Associated Pneumonia (VAP)","Ventilator Weaning","Weaning of Mechanical Ventilation","Sleep Disorders, Circadian Rhythm","Failure, Respiratory","ICU Hospitalization","ICU Sedation",[353,104,358],"2024-10-21",{"date":366,"type":44},"2024-10-23",{"date":368,"type":21},"2025-01-01",{"date":370,"type":21},"2027-07-01",{"name":372,"class":51},"University Hospital, Grenoble"]